Kernal Biologics Revenue, Growth & Competitor Profile

DBA KERNAL BIOLOGICS INC

Company Profile & Annual Report for Kernal Biologics

Access the complete profile.

Kernal Biologics Fast Facts

Revenue	$1 - $10 million    See Exact Annual Revenue
Employees	10 - 100Exact Company Size
Primary Industry	5417 Scientific Research & Development Services
Address	238 Main St Ste 5 Cambridge, MA 02142

Note: Revenues for privately held companies are statistical evaluations.


Kernal Biologics's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Kernal Biologics's annual revenues are $1 - $10 million (see exact revenue data)
• What industry is the company in?
  • Kernal Biologics is classified as operating in the Scientific Research & Development Services industry, NAICS Code 5417.

Kernal Biologics Annual Revenue and Growth Rate

Kernal Biologics	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2025	$1 - $10 million Details in Premium Report
2024
2023
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Kernal Biologics's revenues are gauged from an analysis of company filings.

Kernal Biologics's Income Statement (based on Industry Averages)

Kernal Biologics P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Trademark Applications

Trademark applications show the products and services that Kernal Biologics is developing and marketing. Kernal Biologics doesn't have any recent trademark applications, indicating Kernal Biologics is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
KERNAL Medical, biological, and pharmaceutical preparations for treating cancers, auto-immune diseases, cardio metabolic diseases, infectious diseases, inflammatory diseases, and metabolic diseases; RNA-based therapeutics and therapeutic agents for in vivo, ex vivo, or in situ treatment of cancers, auto-immune diseases, cardio metabolic diseases, infectious diseases, inflammatory diseases, and metabolic diseases; medical, biological and pharmaceutical preparations containing lipid nanoparticles for the prevention and treatment of cancers, auto-immune diseases, cardio metabolic diseases, infectious diseases, inflammatory diseases, and metabolic diseases; RNA-based therapeutics and therapeutic agents for in vitro preparation and in vivo, ex vivo, or on vivo delivery to cell sites; nucleic acid sequences and chemical reagents for medical and veterinary purposes	07/18/2022
KERNAL BIO Medical, biological, and pharmaceutical preparations for treating cancers, auto-immune diseases, cardio metabolic diseases, infectious diseases, inflammatory diseases, and metabolic diseases; RNA-based therapeutics and therapeutic agents for in vivo, ex vivo, or in situ treatment of cancers, auto-immune diseases, cardio metabolic diseases, infectious diseases, inflammatory diseases, and metabolic diseases; medical, biological and pharmaceutical preparations containing lipid nanoparticles for the prevention and treatment of cancers, auto-immune diseases, cardio metabolic diseases, infectious diseases, inflammatory diseases, and metabolic diseases; RNA-based therapeutics and therapeutic agents for in vitro preparation and in vivo, ex vivo, or on vivo delivery to cell sites; nucleic acid sequences and chemical reagents for medical and veterinary purposes	07/18/2022
KERNAL BIOLOGICS Medical, biological, and pharmaceutical preparations for treating cancers, auto-immune diseases, cardio metabolic diseases, infectious diseases, inflammatory diseases, and metabolic diseases; RNA-based therapeutics and therapeutic agents for in vivo, ex vivo, or in situ treatment of cancers, auto-immune diseases, cardio metabolic diseases, infectious diseases, inflammatory diseases, and metabolic diseases; medical, biological and pharmaceutical preparations containing lipid nanoparticles for the prevention and treatment of cancers, auto-immune diseases, cardio metabolic diseases, infectious diseases, inflammatory diseases, and metabolic diseases; RNA-based therapeutics and therapeutic agents for in vitro preparation and in vivo, ex vivo, or on vivo delivery to cell sites; nucleic acid sequences and chemical reagents for medical and veterinary purposes	07/18/2022

See all trademarks and details in the Full Report.

Market Share of Kernal Biologics's Largest Competitors

A competitive analysis shows these companies are in the same general field as Kernal Biologics, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
LEIDOS	Denver, CO	100
NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA	Albuquerque, NM	30
INC RESEARCH	Raleigh, NC	27
RESEARCH FOUNDATION FOR STATE UNIVERSITY OF NEW YORK	Albany, NY	17
FLUOR MARINE PROPULSION	West Mifflin, PA	15
SYNEOS HEALTH	Raleigh, NC	13
ILLUMINA	San Diego, CA	12
UT-BATTELLE	Oak Ridge, TN	11
PRA HOLDINGS	Raleigh, NC	11

Nearby Competitors

These companies are similar in business line and location to Kernal Biologics. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
BROAD INSTITUTE	Cambridge, MA	100
BEIGENE USA	Cambridge, MA	69
ALNYLAM PHARMACEUTICALS	Cambridge, MA	52
SAGE THERAPEUTICS	Cambridge, MA	47
INTELLIA THERAPEUTICS	Cambridge, MA	35
IPSEN BIOPHARMACEUTICALS	Cambridge, MA	34

Future Competition: Kernal Biologics's Fastest Growing Competitors

These companies are in the same general field as Kernal Biologics and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)